I found the field of Pharmacology & Pharmacy very interesting. Saw the article Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer published in 2020. Recommanded Product: 98-97-5, Reprint Addresses Xu, ST; Xu, JY (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China.; Xu, ST; Xu, JY (corresponding author), China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China.. The CAS is 98-97-5. Through research, I have a further understanding and discovery of Pyrazine-2-carboxylic acid
Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic breast cancers without safe and effective therapeutic drugs. The natural product oridonin is reported to be a potential anti-TNBC agent. However, its moderate activity and complex structure hampered its clinical application. In this study, the novel oridonin analogues were first identified by removal of multiple hydroxyl groups and structural simplification of oridonin. The representative analogue 20 exhibited potent anticancer effects. Further structural modification on 20 generated the most potent derivative 56, which possessed 120-fold more potent antiproliferative activity than oridonin in the TNBC cell line HCC1806. Importantly, compound 56 exhibited more potent anticancer activity than paclitaxel in TNBC xenograft nude mice. Moreover, 56 could attenuate the expression of MMP-2, MMP-9, p-FAK, and integrin beta 1 to inhibit TNBC cell metastasis. All results suggest that compound 56 may warrant further investigation as a promising candidate agent for the treatment of TNBC.
Recommanded Product: 98-97-5. Welcome to talk about 98-97-5, If you have any questions, you can contact Yao, H; Xie, SW; Ma, XQ; Liu, JK; Wu, HY; Lin, AJ; Yao, HQ; Li, DH; Xu, ST; Yang, DH; Chen, ZS; Xu, JY or send Email.
Reference:
Patent; Chevron Research Company; US4732894; (1988); A;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem